Company / Cash & Equivalents
NovoCure Ltd Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$93.5M
FY2025
5-year range
$93.5M / $240.8M
FY2021-FY2025
Trend
-42.9%
vs FY2024
Sector context
#113 of 152
Health Care
What the data says
At $94M, NovoCure Ltd's cash & equivalents ranks #113 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $79M in FY2017 to $241M in FY2023.
Based on SEC 10-K filings.
$94M in FY2025 with a 5-year CAGR of -16.8%.
Declined from $241M to $94M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -6.7%
- 5-Year CAGR
- -16.8%
- 10-Year CAGR
- -
Sector benchmark
#113 of 152 in Health CareTop 74% of 152This company $93.5M Sector average $1.2B
▼
-92.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -16.8%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 42.9% year-over-year.
- Ranks #113 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $93.5M | -42.9% |
| FY2024 | $163.8M | -32.0% |
| FY2023 | $240.8M | +108.8% |
| FY2022 | $115.3M | -44.8% |
| FY2021 | $208.8M | -11.0% |
| FY2020 | $234.7M | +32.3% |
| FY2019 | $177.3M | +26.1% |
| FY2018 | $140.6M | +78.9% |
| FY2017 | $78.6M | -21.2% |
| FY2016 | $99.8M | -16.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026